Apixaban Price Trend

Apixaban Price Trend, Index and Forecast

Track the latest insights on apixaban price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.

Apixaban Prices Outlook Q2 2025

• USA: US$ 44,617/MT
• China: US$ 24,295/MT
• Germany: US$ 55,269/MT
• India: US$ 30,369/MT
• Korea: US$ 43,946/MT

Apixaban Price Chart

Get real-time access to monthly/quaterly/yearly prices, Request Sample

During the second quarter of 2025, apixaban prices in the USA reached 44,617 USD/MT in June. Apixaban prices in the United States followed a steady upward trend, primarily driven by consistent demand for cardiovascular and stroke prevention therapies. The increase was supported by stable domestic consumption, incremental rises in API production costs, and regulatory compliance expenses. While the presence of generics helped temper sharp fluctuations, overall pricing remained firm due to steady supply chain operations and healthcare utilization patterns. The quarter reflected a controlled rise in prices aligned with input costs and therapeutic demand.

During the second quarter of 2025, apixaban prices in China reached 24,295 USD/MT in June. Apixaban prices in China continued to grow, building on the strong sales and market expansion seen in prior years. Ongoing demand linked to cardiovascular treatments reinforced robust API procurement, while limited competition among major domestic manufacturers sustained pricing strength. Supply remained consistent, though manufacturers closely monitored fermentation input costs, which added slight upward pressure.

During the second quarter of 2025, apixaban prices in Germany reached 55,269 USD/MT in June. Apixaban prices remained relatively firm, reflecting stable demand from the country’s advanced healthcare system and tight patent-related supply controls. Industrial pricing is influenced by fermentation-based API production costs and ongoing delays in the generic pipeline, which help sustain pricing resilience. Distribution through hospital and retail pharmacy channels exhibited consistent procurement patterns, minimizing volatility.

During the second quarter of 2025, apixaban prices in India reached 30,369 USD/MT in June. Apixaban price in India exhibited moderate firmness, supported by consistent demand from hospitals and specialty clinics focused on cardiovascular treatments. Domestic manufacturers and importers—primarily sourcing APIs from local and Chinese producers—ensured a stable supply environment. Currency fluctuations and elevated formulation costs contributed to slight upward pricing pressure. Overall, the pricing trend reflected a balanced mix of supply-side assurance and steady downstream demand.

During the second quarter of 2025, apixaban prices in Korea reached 43,946 USD/MT in June. Apixaban prices remained stable to slightly firm, underpinned by consistent demand from the country’s well-established healthcare infrastructure. While early domestic generic activity introduced modest competitive pressure, reliance on imported APIs and recent approvals for expanded therapeutic indications helped sustain price levels. The market exhibited a balanced trend, shaped by steady healthcare utilization and dependable supply chains, reinforcing a resilient pricing environment throughout the quarter.

Apixaban Prices Outlook Q1 2024

• Korea: US$ 43,000/Ton

The price of apixaban in the Korea for Q1 2024 reached 43,000 USD/Ton in March.

Regional Coverage

The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing the apixaban prices.

Global Apixaban Price Trend

The report offers a holistic view of the global apixaban pricing trends in the form of apixaban price charts, reflecting the worldwide interplay of supply-demand balances, international trade policies, and overarching economic factors that shape the market on a macro level. This comprehensive analysis not only highlights current price levels but also provides insights into historical price of apixaban, enabling stakeholders to understand past fluctuations and their underlying causes. The report also delves into price forecast models, projecting future price movements based on a variety of indicators such as expected changes in supply chain dynamics, anticipated policy shifts, and emerging market trends. By examining these factors, the report equips industry participants with the necessary tools to make informed strategic decisions, manage risks, and capitalize on market opportunities. Furthermore, it includes a detailed apixaban demand analysis, breaking down regional variations and identifying key drivers specific to each geographic market, thus offering a nuanced understanding of the global pricing landscape.

Europe Apixaban Price Trend

Q2 2025:

Apixaban prices in Europe remained relatively stable, with modest fluctuations driven by changes in manufacturing costs and the availability of active pharmaceutical ingredients (APIs). Demand across key markets, such as Germany, France, and Italy, remained steady due to the widespread use of anticoagulant therapies. Supply chains across the region were largely uninterrupted, supporting consistent availability. Overall, the pricing environment reflected balanced market conditions aligned with steady therapeutic demand and regional production dynamics.

Q1 2024:

European apixaban prices are examined, highlighting the market-specific influences in the region, such as stringent environmental regulations, the competitive landscape, and import-export imbalances that significantly affect pricing structures.

This analysis can be extended to include detailed apixaban price information for a comprehensive list of countries.

North American apixaban Price Trend

Q2 2025:

In North America, apixaban prices exhibited mild fluctuations, primarily influenced by variable raw material and manufacturing costs. Steady demand from the healthcare sector supported price stability across the region. While regulatory compliance and pharmaceutical manufacturing standards continued to drive operational expenses, the presence of both branded and generic versions helped moderate any significant price shifts. Supply chains remained largely undisrupted, ensuring consistent market availability.

Q1 2024:

The analysis of apixaban prices in North America delves into the regional industry dynamics, encompassing the impact of local production capacities and the trade flows between North America and other significant global markets.

Specific apixaban historical data within the United States and Canada can also be provided.

Middle East and African apixaban Price Trend

Q2 2025:

The report explores the apixaban trends and apixaban price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices. 

In addition to region-wise data, information on apixaban prices for countries can also be provided.

Asia Pacific Apixaban Price Trend

Q2 2025:

In the Asia-Pacific region, apixaban prices remained relatively stable, with minor fluctuations influenced by active pharmaceutical ingredient (API) costs and regional production dynamics. Key manufacturing hubs, such as India and China, maintained consistent output, supported by steady demand from both domestic and export markets. However, robust supply chains and growing adoption in cardiovascular therapies helped sustain balanced market conditions. Overall, prices reflected stable demand, aligned with trends in raw materials and manufacturing efficiencies across the region.

Q1 2024:

The apixaban pricing trends in Asia Pacific are examined, reflecting the role of the region as a major global production hub and consumer market, with price dynamics heavily influenced by supply chain efficiencies, regional demand surges, and policy shifts in major economies.

This apixaban price analysis can be expanded to include a comprehensive list of countries within the region.

Latin American apixaban Price Trend

Q2 2025:

Latin America's apixaban market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in apixaban prices. Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting the region's ability to meet international demand consistently. Moreover, apixaban index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing apixaban pricing trends in this region.

Q1 2024:

The analysis of apixaban prices in Latin America provides a detailed overview, reflecting the unique market dynamics in the region influenced by economic policies, industrial growth, and trade frameworks.

This comprehensive review can be extended to include specific countries within the region.

Apixaban Price Trend, Market Analysis, and News

IMARC's latest publication, “Apixaban Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2025 Edition,” presents a detailed examination of the apixaban market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of apixaban at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents a detailed apixaban price trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting apixaban pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.

Apixaban Industry Analysis

The global apixaban market size reached US$ 11.77 Billion in 2024. By 2033, IMARC Group expects the market to reach US$ 21.64 Billion, at a projected CAGR of 6.65% during 2025-2033.

• The increasing prevalence of cardiovascular diseases (CVDs) is driving up demand for anticoagulant treatments such as apixaban. According to THE AMERICAN HEART ASSOCIATION (AHA), it is estimated that roughly 127.9 Million Americans (48.6%) ≥20 years of age have CVD, including coronary heart disease, heart failure, stroke, or hypertension. Excluding hypertension, about 28.6 Million American adults (9.9%) have some type of CVD. The prevalence of diseases like deep vein thrombosis (DVT), pulmonary embolism (PE), and atrial fibrillation is rising as a result of sedentary lifestyles, bad diets, and aging populations.
• The global aging population is one of the main factors propelling the apixaban industry. Apixaban is well-positioned to satisfy the needs of the aging population, which will propel market expansion thanks to its good safety and effectiveness profile. According to the WORLD HEALTH ORGANIZATION, between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. Moreover, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. As they are more likely to develop thromboembolic disorders, older persons require effective anticoagulant medications. The need for drugs that treat and prevent age-related illnesses like DVT and atrial fibrillation is growing as life expectancy rises and the world's population ages.
• The market for Apixaban is also being driven by more knowledge and understanding of the advantages of anticoagulant therapy in preventing major thromboembolic events. Higher adoption rates are the result of initiatives by pharmaceutical companies, patient advocacy groups, and healthcare organizations to inform medical professionals and patients about the benefits of novel anticoagulants like Apixaban.

Apixaban News

The report covers the latest developments, updates, and trends impacting the global apixaban industry, providing stakeholders with timely and relevant information. This segment covers a wide array of news items, including the inauguration of new production facilities, advancements in apixaban production technologies, strategic market expansions by key industry players, and significant mergers and acquisitions that impact the apixaban price trend.

Latest developments in the Apixaban industry:

• In November 2023, THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM) and the AMERICAN HEART ASSOCIATION published a study in November 2023 that found the widely available blood thinner apixaban significantly reduced stroke in at-risk patients with a type of atrial fibrillation that can only be detected by a pacemaker or other implanted cardiac electronic device.

Product Description

Apixaban is an anticoagulant medication, often referred to as a blood thinner, used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In patients who have had hip or knee replacement surgery, it is used for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT can cause PE. By blocking Factor Xa, a crucial enzyme in the coagulation process, apixaban prevents blood clots from forming. Unlike some previous anticoagulant drugs, it is given orally and is known to have a predictable anticoagulant effect, so it does not require routine monitoring. The dosage may change based on the patient's renal function, the particular ailment being treated, and other personal circumstances.

Report Coverage

Key Benefits for Stakeholders:

• IMARC’s report presents a detailed analysis of apixaban pricing, covering global and regional trends, spot prices at key ports, and a breakdown of FOB and CIF prices.
• The study examines factors affecting apixaban price trend, including input costs, supply-demand shifts, and geopolitical impacts, offering insights for informed decision-making.
• The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
• IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The apixaban price charts ensure our clients remain at the forefront of the industry.